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We evolved muscarinic receptors in yeast to generate a family of
G protein-coupled receptors (GPCRs) that are activated solely by a
pharmacologically inert drug-like and bioavailable compound (clo-
zapine-N-oxide). Subsequent screening in human cell lines facili-
tated the creation of a family of muscarinic acetylcholine GPCRs
suitable for in vitro and in situ studies. We subsequently created
lines of telomerase-immortalized human pulmonary artery smooth
muscle cells stably expressing all five family members and found
that each one faithfully recapitulated the signaling phenotype of
the parent receptor. We also expressed a Gi-coupled designer
receptor in hippocampal neurons (hM4D) and demonstrated its
ability to induce membrane hyperpolarization and neuronal silenc-
ing. We have thus devised a facile approach for designing families
of GPCRs with engineered ligand specificities. Such reverse-engi-
neered GPCRs will prove to be powerful tools for selectively
modulating signal-transduction pathways in vitro and in vivo.
cell engineering  molecular evolution  receptorome
Because of the assorted cellular responses directed by them, theirnumber, and the ease of which they are pharmacologically
screened, the superfamily of G protein-coupled receptors (GPCRs)
is one of the most therapeutically important targets in the proteome
(1). However, the potential of this family is restricted by our ability
to assess their function, which currently involves transgenic, knock-
out, and/or in vivo studies with selective drugs. Genetic studies are
frequently limited to loss-of-function phenotypes, whereas nonse-
lectiveness of a drug often interferes with interpretation of phar-
macological studies. Knowledge of the roles of the individual family
members is being bolstered by the ongoing creation of knockout
mice for many GPCRs. Selective activation of individual GPCR
subtypes in a defined tissue, in either a knockout or wild-type
animal, is currently problematic but, if possible, would serve to
complement present findings by providing novel insights into
disease states resulting from overstimulation of certain signaling
pathways.
One approach to this problem has been to rationally modify
receptors to favor synthetic over natural substrate/ligand recogni-
tion, and subsequently, these mutant proteins have been used as
bio-tools to study protein function in complex biological environ-
ments (2, 3). At the forefront of such modified GPCRs is Ro1, a
Gi/o-coupled  opioid receptor activated by a synthetic but not a
native ligand, which has been conditionally expressed in transgenic
mice to study cardiac function after its selective activation (4). Such
mutant receptors, like Ro1, have been classified as receptors
activated solely by synthetic ligands (RASSLs), because they are
activated by synthetic ligands but not by their endogenous ligands
(5). RASSLs, as in the case of Ro1, have been demonstrated to be
valuable tools (4, 6); however, because the synthetic ligand fre-
quently has high affinity and/or potency at the native receptor (5,
7, 8), this potentially limits their usefulness in vivo, at least in tissues
with a wild-type receptor present. In this context, we sought to
develop designer receptors exclusively activated by a designer drug
(DREADD), or simply ‘‘designer’’ receptors, which represent
receptors that are activated solely by a synthetic ligand(s) possessing
minimal or no biologic activity.
In this study, we present a directed molecular evolution
approach, which facilitated the creation of a family of muscarinic
receptors that is potently activated by the pharmacologically
inert compound clozapine-N-oxide (CNO) but not by its native
ligand acetylcholine (ACh). We further demonstrate that such
designer muscarinic receptors are active in a variety of native and
artificial cellular contexts. We thus provide a validated and
unbiased approach for generating GPCRs with defined ligand
specificities and for proof of concept have created a family of
muscarinic ACh receptor (mAChR) DREADDs having promise
as unique biological tools to study either receptor-specific func-
tions [e.g., , human mAChR DREADD subtype 3 (hM3) vs. hM1]
or general downstream signaling (e.g., Gq/11 vs. Gi/o) emanating
from the activated GPCR.
Results
Directed Molecular Evolution of Rat M3 Receptor in Yeast. We set out
to develop an M3 DREADD that was responsive to a synthetic
ligand of choice by using a directed molecular evolution approach.
CNO was selected as the synthetic ligand because: (i) its parent
compound, clozapine, has high affinity to M3 receptors and,
therefore, we predicted few mutations would be required to permit
CNO to be a potent agonist; (ii) CNO is highly bioavailable in
rodents and humans (9, 10); and (iii) importantly, CNO is a
pharmacologically inert molecule lacking appreciable (1 M)
affinity for receptors [ref. 11 and supporting information (SI) Fig.
6]. For initial studies, a modified rat M3 receptor containing a
sizable deletion in its third intracellular loop [(i3); rM3i3] was used
(SI Fig. 7). The rat M3i3 receptor has been previously demon-
strated to be functionally expressed in Saccharomyces cerevisiae
genetically modified to enable ligand activation of heterologously
expressed mammalian GPCRs to engage the pheromone signaling
pathway to promote growth on selective medium (12).
By means of random mutagenesis, we created a large library of
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mutant rM3i3 receptors and screened them initially for activation
by clozapine, which has high affinity but which is an exceedingly
weak partial agonist at native M3 receptors. Ten independent
clones, eight of which contained, among other mutations, a
Y148X3.33 mutation, were isolated from this initial screen to
identify rM3i3 receptor mutants activated by clozapine (see Ma-
terial and Methods for details). Whereas yeast expressing wild-type
rM3i3 receptor responded only to either ACh or carbachol (CCh),
an ACh analog, in liquid growth assays, yeast expressing any of the
10 clones were efficaciously activated by clozapine within 10-fold
range of 10 M concentration used to screen the library (Fig. 1 and
SI Table 1). Strikingly, all mutants were defective in their response
(reduced potency) to CCh and/or ACh, with one clone (G6) unable
to be activated by 10 mM ACh (Fig. 1 and SI Table 1). This loss in
ACh potency was serendipitous, because diminished response to
the native ligand is one requirement of a DREADD. Although
most clones tested were not activated by up to 100 M CNO, a
single clone, G2, was found to be mildly responsive to CNO (Fig.
1 and SI Table 1). This was a promising finding, because we
anticipated that clones selected to be activated by clozapine may be
prone to CNO activation as well.
A subset of clones were selected to be remutated to manu-
facture a second-generation library to select for mutants acti-
vated by 1 M CNO (SI Table 1 and SI Materials and Methods).
The second-generation rM3i3 receptor mutants were effica-
ciously activated by CNO with a broad range of potencies
(35–5,000 nM), which invariably was accompanied by a 100-
fold increase in clozapine vs. CNO potency (Fig. 1 and SI Table
1). Again all mutants, with a single exception, had 1,000-fold
reduction in ACh potency (SI Table 1).
A final library was constructed by using a subset of the
second-generation CNO-responsive rM3i3 receptor mutants as
the mutagenesis template and screened with 5 nM CNO to
select for potently activated mutants (SI Table 1 and SI Materials
and Methods). Two clones were isolated that were activated by
CNO and clozapine with potencies of 10 nM and 0.1 nM,
respectively (Fig. 1 and SI Table 1).
Engineering an hM3 Receptor to Be Potently and Efficaciously Acti-
vated by CNO in Human Cells. Using the yeast-based screen, we were
able to greatly enhance the pharmacological attributes of CNO at
the M3 receptor. However, the ultimate goal was to create a
full-length M3 receptor suitable for mammalian use. We next
determined whether the mutants obtained by the yeast screen
would be directly useful in human cells. In mammalian cells,
activation of Gq/11-coupled receptors, like M3 receptor, can be
measured by the accumulation of inositol monophosphate (IP1), a
metabolite of inositol trisphosphate (IP3) produced by phospho-
lipase C  catalyzed hydrolysis of phosphatidylinositol (PI).
CNO was essentially inactive at wild-type rM3i3 transiently
expressed in HEK T cells, whereas selected mutant rM3i3
receptors displayed robust responses to CNO as well greatly
diminished ACh potency (Fig. 2A and SI Table 2). Because many
of the mutants with the highest CNO potencies had high levels
of constitutive activity (Fig. 2 A and SI Table 2), we next screened
a focused library of hM3 receptor mutants in HEK T cells to
generate a receptor that was potently activated by CNO with
minimal constitutive activity.
We chose the Y149C3.33 mutant as an initial template
because, (i) the rM3i3 Y1483.33 was the most consistently
mutated residue to arise in the yeast screen, (ii) the Tyr3.33
residue is known to be important in ligand binding of musca-
rinic ligands (13–15), and (iii) preliminary experiments showed
that mutation of Tyr-1493.33 in hM3 receptor to either Cys or
His similarly increased CNO responsiveness without increas-
ing basal activity, yet the Y149C mutant had 100-fold better
reduction in ACh potency compared with Y149H when ex-
pressed in HEK T cells (Fig. 2 and SI Table 2). Ultimately, we
found the double mutant Y149C3.33/A239G5.46 to be the best
possible combination of mutations to generate a hM3 DRE-
ADD (hM3D) (Fig. 2 and SI Table 2).
Characterization of hM3 DREADD in Immortalized Human Pulmonary
Artery Smooth Muscle Cells (hPASMC). Although smooth muscle
cells endogenously express M3 receptors (16), we found a
particular human hPASMC line, devoid of endogenous musca-
rinic receptors, which would allowed us to investigate hM3D
receptor function in a null but native environment. We were able
Fig. 1. Pharmacological profiles of an rM3i3 receptor mutant selected
during directed molecular evolution for CNO responsiveness. (A) Experimental
design for directed evolution of mammalian GPCRs in yeast to create
DREADDs. (1) Libraries of randomly mutated rM3i3 receptors were produced
by mutagenic PCR; (2) yeast-expressing mutant receptors activated by syn-
thetic ligands (e.g., CNO) were selected for by growth on nutrient deficient
medium; (3) mutants were verified by secondary liquid growth assays in
96-well plates; (4) plasmid DNA was isolated from yeast; (5) clones were
retransformed into yeast to pharmacologically profile mutants by liquid
growth assays, and those with desirable properties were sequenced and
remutagenized for subsequent rounds of selection to yield receptors with
higher potency. (B) Optical density at 650 nm of liquid cultures of yeast
transformed with either wild type, clone ‘‘G2’’ (first library, 10 M clozapine
screen), clone ‘‘9’’ (second library, 1 M CNO screen), or clone ‘‘118’’ (third
library, 5-nM CNO screen) rM3i3 receptors incubated with ACh (■ ), clozapine
(), or CNO (E). Data shown are mean  SEM values of a representative
experiment performed with two independent yeast transformants grown for
each clone.
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to immortalize hPASMCs, as determined by propagating cells
well past senescence, by the stable introduction of the gene
encoding the human catalytic subunit of telomerase, hTERT
(SI Fig. 8). When wild-type hM3 receptors were stably expressed
in immortalized hPASMCs, they faithfully elicited PI hydrolysis,
Ca2 mobilization and ERK-1/2 phosphorylation (see below and
SI Materials and Methods for assay description) after ACh
treatment (Fig. 3 and SI Tables 3–5). Significantly, the hM3D
receptor stably expressed in immortalized hPASMCs was po-
tently (20–30 nM) and efficaciously activated by CNO (Fig. 3
A and B and SI Tables 3 and 4). The hM3D was found to have
a severe reduction (40,000-fold) in ACh potency compared
with the wild-type receptor (Fig. 3 and SI Tables 3 and 4).
Because some interactions between drug and receptor result in
the onset of some but not all GPCR-related functions (17), we
wanted to test whether hM3D receptors could stimulate distinct
downstream pathways after CNO treatment. A common signaling
event radiating from activated GPCRs is the downstream phos-
phorylation of the MAPK proteins, ERK-1/2, resulting from the
association of the MAPK--arrestin complex with the activated
receptor (1). Treatment with 1 M ACh but not CNO resulted in
an enhanced level of ERK-1/2 phosphorylation in hPASMCs
expressing hM3 receptors (Fig. 3C). Conversely, hPASMCs express-
ing hM3D receptors responded only to CNO under the same
conditions (Fig. 3D). Together, these experiments demonstrate that
the hM3D receptor, created through the mutation of Y149C3.33/
A239G5.46, fits the definition of a DREADD receptor.
Creation of a Family of Designer Muscarinic Receptors. Examination
of protein alignments of mammalian mAChR family members
revealed that Y3.33 and A5.46 are strictly conserved (data not
shown). We also showed mutation of Y6.51, a similarly strictly
conserved residue, enhances the agonistic properties of clozap-
ine-like drugs in two distinct family members (SI Table 2 and ref.
18). Taken together, we hypothesized that introduction of Y3.33C
and A5.46G mutations in the other mAChR family members
would allow CNO to activate these as well.
We individually expressed human M1, 2, 4, and 5 DREADDs in
immortalized hPASMCs to test whether CNO could similarly
activate these receptors. Like the hM3 receptor, we found that
substitution of Tyr3.33/Ala5.46 into the other mAChR family mem-
bers successfully transformed these receptors into CNO-activated
DREADDs (Fig. 4A and SI Tables 3 and 4). Receptor activation
remained sensitive, albeit with reduced potency, to the nonselective
mACh receptor antagonists, atropine and ()-quinuclidinyl ben-
zilate, as monitored by Ca2 mobilization (SI Table 6). We found
treatment of immortalized hPASMCs with pertussis toxin, an
irreversible Gi/o inhibitor, selectively abolished the Ca2 response in
those cells expressing hM2 and hM4 compared with hM1, 3, and 5
receptors (Fig. 4B and data not shown). Additionally, treatment of
CNO selectively reduces forskolin-stimulated cAMP formation in
hPASMCs expressing hM2D receptors with a potency similar to
that seen by Ca2 mobilization assays (SI Materials and Methods and
SI Tables 4 and 7). Therefore, hM2 and hM4 receptors retain their
coupling properties when expressed in hPASMCs and presumably
activate phospholipase C  by G subunits (19).
CNO Silences Hippocampal Neurons Expressing hM4D Receptors. M4
receptors coupled to Gi/o and Gi/o-coupled responses are in-
creasingly used for neuronal silencing; we next determined
whether the hM4D could induce a G protein inward-rectifying
Fig. 2. FocusedscreeningofhM3 receptormutants tooptimizeCNOstimulation
of PI hydrolysis in HEK T cells. (A) Receptor-activated PI hydrolysis in HEK T cells
transfectedwithathird-generationclone ‘‘118’’ () identifiedbytheyeast screen
and wild-type rM3i3 receptor (■ ) treated with ACh (Upper) or CNO (Lower). (B)
Similarly, wild-type (■ ) human M3 receptors with the indicated single Y149H ()
and Y149C (F) or multiple mutations [Y149C, A239G (E); hM3 DREADD], found in
yeast screen clones, were transiently expressed in HEK T cells to measure receptor
activation after treatment with either ACh (Upper) or CNO (Lower). Data of
accumulated radiolabeled inositol 1-phosphate ([3H]-IP1) are normalized to max-
imal ACh-mediated response in HEK T cells expressing either wild-type rM3i3 (A)
or wild-type hM3 (B) receptors. Values shown are mean  SEM from representa-
tive assays performed in duplicate.
Fig. 3. Functional characterization of HA-epitope tagged wild-type and
DREADD hM3 receptors in immortalized hPASMC. (A) Drug-induced PI hydro-
lysis in immortalized hPASMCs stably expressing wild-type (hM3) or DREADD
(hM3D) receptors. Shown are mean  SEM values of a representative exper-
iment performed in duplicate comparing [3H]-IP1 accumulation after ACh or
CNO treatment of hM3 (■ or F, respectively) or hM3D ( and E, respectively)
cells. (B) Calcium mobilization resulting from delivery of ACh or CNO to hM3
(■ or F, respectively) or hM3D ( or E, respectively) expressing immortalized
hPASMCs. A representative experiment, performed in quadruplicate, with
mean values of Ca2 mobilization in relative fluorescent units (RFU), is shown.
(C and D) A representative experiment determining change in ERK-1/2 phos-
phorylation compared with p90 ribosomal S6 kinase loading control after
incubating 1 M of the indicated drugs for 5 min with immortalized hPASMCs
expressing either wild-type (C) or DREADD hM3 (D) receptors by immunoblot
(Upper) with quantification of ERK-1/2 phosphorylation (Lower) from three
independent experiments with significant differences (*, P  0.001) between
drug and vehicle treatment as determined by one-way ANOVA is shown.
















potassium channel (GIRK) response in hippocampal neurons.
Additionally, because mAChR family members are present, to a
varying extent, in the brain and have been implicated in many
processes, mACh DREADDs, expressed individually in isolated
neuronal regions would be ideal tools to evaluate their roles in
this multifarious background. Therefore, we investigated hM4D
receptor functionality in hippocampal neurons in which Gi/o
coupled receptors are known to induce neuronal silencing by
activation of GIRK (20).
We first verified that the hM4D receptor could modify GIRK
currents in HEK cells transiently expressing GIRK1/2 subunits
in combination with hM4D receptor. As a control, we found that
10 M CCh could induce currents in HEK cells transfected with
GIRK1/2 subunits and wild-type hM4 receptors, whereas as little
to no current was found in cells treated with the same concen-
tration of CNO (Fig. 5 A and B Upper). As anticipated, CNO
compared with CCh, which had no effect, selectively activated
GIRK channels in HEK cells that hM4D receptors were coex-
pressed (Fig. 5 A and B Lower).
We next examined whether this behavior was recapitulated in
cultured hippocampal neurons. When wild-type hM4 receptors
were transiently expressed in hippocampal neurons, we found that
CCh, but not CNO, induced hyperpolarization (Fig. 5 C and D
Upper). Significantly, CNO treatment of culture hippocampal neu-
rons transiently expressing hM4D receptor also resulted in neuronal
hyperpolarization (Fig. 5 C and D Lower). Expression of hM4D
receptors in these neurons did not prevent CCh from modulating
hyperpolarization through endogenous receptors (Fig. 5C and data
not shown), suggesting that expression of hM4D does not impede
native receptor function. Additionally, CNO can selectively prevent
action potential firing in cultured hippocampal neurons expressing
hM4D receptors (Fig. 5E) without significantly altering resting
membrane potential in untreated infected neurons (Fig. 5F). These
experiments clearly establish the unique ability of CNO to exclu-
sively activate a cellular response in cells exogenously expressing
hM4D receptors and demonstrate their utility as a tool for in vivo
neuronal silencing.
Discussion
Here we demonstrate that directed molecular evolution can be
used to engineer a GPCR to be potently and efficaciously
activated by a synthetic ligand that is pharmacologically inert.
We extend this approach to show that an entire family of GPCRs,
in this case the human muscarinic receptor family, can be created
to be activated by an inert ligand. We also show that the signal
transduction pathways and novel pharmacologies are faithfully
recapitulated in a variety of cellular contexts including smooth
muscle cells and hippocampal neurons. We suggest that at least
one of these designer receptors, hM4D, will prove useful for
Fig. 4. Transformation of CNO response in mACh receptor family members.
(A) Representative Western blots detecting either phosphorylated ERK-1/2 or,
as a loading control, p90 ribosomal S6 kinase 1, after a 5-min application of a
1 M final concentration of the indicated drugs to immortalized hPASMCs
expressing wild-type or DREADD hM1, hM2, hM4, and hM5 receptors, as
indicated. (B) Ca2 mobilization response in immortalized hPASMCs express-
ing either the Gq/11-coupled hM3 (black symbols; Left) or the Gi/o-coupled
receptors hM2 and hM4 (blue and red symbols, respectively; Right) is shown.
Cells were treated with ACh after overnight incubation with either vehicle
control (solid symbols) or pertussis toxin or pertussis toxin (open symbols) on
receptor-mediated Ca2 release. Values shown are mean  SEM from a
representative experiment performed in triplicate.
Fig. 5. Characterization of hM4 DREADD on GIRK channel activation, mem-
brane hyperpolarization, and neuronal silencing. (A) Sample traces of recep-
tor-induced GIRK currents in HEK293 cells cotransfected with GIRK1/2 channel
subunits and either hM4 (Upper) or hM4D (Lower) receptors and treated with
either 10 M CCh or CNO at a holding potential of 60 mV as described in SI
Materials and Methods. (B) Comparison of induced GIRK channel currents at
60 mV when coexpressed with either hM4 or hM4D receptors. (C) Sample
traces of CCh- and CNO-induced voltage changes in cultured hippocampal
neurons infected with either hM4 (Upper) or hM4D (Lower). (D) Summary of
the hM4- and hM4D-induced voltage changes by CCh and CNO. (E) Sample
traces of hippocampal neurons spontaneously firing action potentials. In the
presence of hM4D receptors (lower trace), application of CNO induces hyper-
polarization and neuronal silencing. (F) Comparison between the resting
membrane potential of hM4D receptor-expressing and control hippocampal
neurons, indicating that the expression of hM4D receptors does not change
the resting membrane potential without activation of the receptor. Number
of cells tested is indicated in parentheses with mean  SEM shown.
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neuronal silencing in vitro and in vivo. Using this general
approach, it should be possible to eventually evolve GPCRs to
bind any arbitrary drug-like small molecule by essentially de-
signing the ‘‘lock’’ (GPCR) to fit the ‘‘key’’ (the ligand).
There are a number of technical considerations that should be
borne in mind when embarking on a campaign to reverse engineer
a GPCR. We found, in general, that most of the key ‘‘transforming’’
residues were found in the initial screen and, compared with those
mutants found in later screens, more of these mutants had un-
changed basal activity when expressed in human cells. Therefore, it
is advisable to screen a large initial library, which is likely to have
the highest impact in unearthing important and easily identifiable
residues, as well as counter screen promising mutants in mamma-
lian cells early on to reduce the risk of evolving constitutively active
receptors. A distinct advantage to directed evolution by using
randomized libraries is that is unbiased. However, the screen can be
significantly enhanced with prior knowledge of residue importance.
Not surprisingly, four residues (Y3.33, T5.42, W6.48, and Y6.51) in-
volved in binding to ACh and other mAChR ligands (13, 21) were
mutated in our screen, illustrating that special attention should be
given to these residues or local helical regions. Intriguingly, this
lends evidence to the notion that clozapine-related ligands, such as
clozapine, CNO, and olanzapine (data not shown), which readily
activate the hM3D receptor, may either bind distinctly within the
ACh orthosteric site or, as previously suggested, are allosteric
ligands (18). Similarly, it is potentially worthwhile to perform
saturating mutagenesis at residue ‘‘hot spots’’ to optimize function-
ality, because we found multiple substitutions at one residue (e.g.,
Y148C/H/N3.33) enhanced rM3i3 receptor activation by clozapine/
CNO in yeast and considering most single-nucleotide mutations
within a codon will not change the translated amino acid to all of
the other possible amino acids. For example, in our initial library,
if all possible single-nucleotide mutations were introduced within
the Y148 codon, only 7 of 19 possible amino acid substitutions
would have been achieved. In this way, subsequent libraries would
be seeded with an optimized receptor while avoiding propagation
of unimportant secondary mutations.
The first reported receptor that can be considered a DREADD
is a 2-adrenergic receptor rationally mutated at the highly con-
served residue D113S3.32. This mutant had a severe reduction in
both potency and efficacy to catecholamine agonists but instead was
fully activated, albeit with low potency (40 M), by compounds
foreign to the wild-type receptor (22). More recently, rational
mutation of F435A6.55 in the histamine H1 receptor (23) and
D100A3.32 of the 5-HT4 receptor (8) [the first Gq/11 and Gs-coupled
receptors activated solely by synthetic ligands (RASSLs), respec-
tively] enhanced the potency for synthetic ligands and reduced
affinity and potency for their native ligands, although not nearly to
same extent as the mACh DREADDs described here.
Here, guided by mutations arising from directed molecular
evolution in yeast, we discovered Y3.33C and A5.46G mutations to
be sufficient to generate a human hM3 DREADD that re-
sponded potently, efficaciously, and selectively to CNO vs. ACh
by PI hydrolysis, Ca2 mobilization, and ERK-1/2 phosphoryla-
tion in a physiologically relevant background. Fortuitously,
mutations at these same two conserved residues effectively
switched the responsiveness of all other human mAChR family
members so that CNO selectively activated them in two inde-
pendent cellular settings by using a variety of signaling readouts.
Interestingly, this dramatic enhancement of functional activation
is accompanied by a minimal (5-fold) increase in CNO affinity,
which remains to be explored (not shown).
Knockout of individual or combinations of mACh receptors in
mice has given enormous insight into function and possible
pathophysiologies resulting to disruption of these receptors (16).
However, these studies provide limited insight into what role
either acute or chronic receptor overstimulation plays in disease
states. For example, studies have shown that M1 and M4 knock-
out mice have increased locomotor activity and modified dopa-
mine levels and/or release (24–26); however, it is difficult to
decipher whether and which receptors exert a tonic check for
movement or whether overstimulation of either receptor may
participate in Parkinson’s disease. The unique ability of CNO
to induce neuronal silencing in neurons that express hM4
DREADD will facilitate studies aimed at investigating the role
of defined neuronal populations in a large number of physio-
logical and pathological processes.
Materials and Methods
Plasmid Construction and Materials. p416GPD was purchased from
American Type Culture Collection. p416GPD-rM3i3R and
pMP290 were previously described (12). pcDNA3.1() contain-
ing inserts of each human hM1–5 receptor was obtained from
(University of Missouri Rolla cDNA Resource Center, Rolla,
MO). Single codon mutations were sequentially introduced into
pcDNA3.1() constructs containing the human muscarinic re-
ceptors by Quikchange Site-directed mutagenesis kit (Strat-
agene, La Jolla, CA). hM1 and hM3 receptors were subcloned
into the BamHI and XbaI sites of a modified pcDNA3.1(),
pcDNA3.1()-EcoRI, which contains an additional EcoRI site
3 of the XbaI site. Retroviral vectors pBabepuro (27) and
pHA-Babepuro were generated by the addition of a Kozak
sequence and sequence encoding an HA epitope tag with an
initiating methionine (MYPYDVPDYA) into the BamHI site of
pBabepuro. pcDNA3.1()-EcoRI-hM1 and pcDNA3.1()-
EcoRI-hM3 wild-type and mutant receptors were digested with
BamHI and EcoRI and inserted into pBabepuro and, in the case
of hM3, also pHA-Babepuro digested with the same enzymes.
pcDNA3.1()-hM2 was digested with EcoRI and XhoI and
inserted into EcoRI and SalI sites of pBabepuro. pcDNA3.1()-
hM4 and pcDNA3.1()-hM5 were digested with BamHI and
XhoI and inserted into BamHI and SalI sites of pBabepuro.
GIRK1/2 subunits were cloned into pcDNA3.1. Sindbis virus
vector SinRep(nsP2S726) and helper DH-BB were kindly pro-
vided by P. Osten (Max Planck Institute for Medical Research,
Heidelberg, Germany) (28). Human M4 was cloned into the PmlI
site of SinRep(nsP2S726) after digesting of pcDNA3.1()-hM4
with PmeI. pBabehygro-flag-hTERT was previously described
(29). Sequence identity was determined by automated sequenc-
ing (Cleveland Genomics, Cleveland, OH).
Mutant libraries were generated by mutagenic PCR by using
GeneMorph II Random Mutagenesis kit (Stratagene) following the
manufacturer’s protocol by using 30 cycles and 250 ng of
p416GPD-rM3i3R DNA template and primers 5-ACACCAA-
GAACTTAGTTTCGACGG and 5-GGCGTGAATGTA-
AGCGTGAC, which resulted in an empirical mutational rate of
3.5 mutations per kilobase. Mutagenic products were digested
with XhoI and XbaI and cloned into the same sites in p416GPD and
then transformed into XL10 Gold bacteria (Stratagene) to amplify
plasmid library. First-generation library (3 	 104 independent
clones, with 6 	 104 colonies screened) used wild-type p416GPD-
rM3i3R as template. Second-generation library (7 	 104 inde-
pendent clones, with 2.5 	 104 colonies screened) was amplified
from equimolar amounts of plasmid clones ‘‘B4,’’ ‘‘B11,’’ ‘‘G2,’’
‘‘G6,’’ and ‘‘G15,’’ chosen for their diversity in mutations and
alteration in drug response. Similarly, plasmid clones ‘‘3,’’ ‘‘7,’’ ‘‘8,’’
‘‘9,’’ and ‘‘16’’ were used to produce the third-generation library
(6 	 105 independent clones, with 8 	 104 colonies screened).
L-Quinuclidinyl[phenyl-4-3H]benzilate (36.5 Ci/mmol) was
purchased from GE Healthcare Biosciences (Piscataway, NJ).
All other chemicals [()-quinuclidinyl benzilate, CNO, ACh,
CCh, and atropine, 3-amino-1,2,4-triazole (3-AT)] and amino
acids were purchased from Sigma–Aldrich (St. Louis, MO).
Synthetic yeast media was purchased from Q-BIOgene (Irvine,
CA) and BD Biosciences (San Diego, CA).
















Yeast Library Screen and Growth Assays. Plasmid library DNA was
transformed into S. cerevisiae strain MPY578q5 (12) by a high-
efficiency procedure (30) and selected for growth at 30°C for 3–4
days in the presence 10 M clozapine, 1 M CNO, or 5 nM CNO
for first-, second-, and third-generation libraries, respectively, on
agar plates containing yeast assay buffer [synthetic complete (SC)
media (pH 6.9) lacking uracil and histidine and supplemented with
20 mM 3-AT]. Colonies were then submitted to a secondary
liquid-assay screen in which they were grown overnight in SC media
without uracil, pelleted, washed with water, then diluted in yeast
assay buffer to a final concentration of OD650 0.003. Diluted yeast
(150 l) was added to a 96-well plate containing 50 l of yeast assay
buffer supplemented with varying drug concentrations and grown
with mild agitation at 25°C for 3 days, at which time the plate was
read at OD650 on a microplate reader by using SOFTmax Pro 4.3.1
software (Molecular Devices, Sunnyvale, CA). Plasmids were iso-
lated from responsive colonies as described (31) and retransformed
into MPY578q5 and/or sequenced. Pharmacological profiling of
clones was performed by liquid assay by using two to three
independent transformants and typically repeated two to six times.
Viral Production, Cell Line Establishment, and Cell Culture. Human
embryonic kidney strain, HEK T, was purchased from American
Type Culture Collection (#CRL-11268; Manassas, VA),
hPASMCs were purchased from ScienCell (San Diego, CA), and
HEK strain 293TS cells were kindly provided by C. M. Counter
(Duke University, Durham, NC). Amphotropic retrovirus was
produced by cotransfecting a 6-cm plate of 293TS grown in DMEM/
10% FBS with 1 g of pBabehygro-flag-hTERT with 1 g of the
amphotropic packaging plasmid pCL-10A1 (Imgenex, San Diego,
CA) by using FuGene6 (Roche, Indianapolis, IN) transfection
reagent. Virus-containing medium was collected between 24 and
60 h after transfection, filtered with a sterile 0.45-m filter, sup-
plemented with a final concentration of 4 g/ml polybrene (Sigma),
and incubated with hPASMCs plated on 0.2% porcine gelatin-
coated plates for 6–12 h to infect. After hTERT infection,
hPASMCs were then media-changed into Smooth Muscle Cell
Medium (ScienCell) and 36–48 h after infection, cells were selected
and subsequently grown in Smooth Muscle Cell Medium and 50
g/ml hygromycin B. The first confluent plate under selection was
designated as population doubling 0. hPASMCs were grown on
0.2% gelatin-coated plates in hygromycin B-supplemented Smooth
Muscle Cell Medium for immortalization study. Polyclonal
hPASMCs stably expressing human mACh receptors were created
by retroviral infection, as described above by using pBabepuro or
pHA-Babepuro constructs, and grown on 0.2% gelatin-coated
plates in DMEM/10% FBS supplemented with 1 g/ml puromycin.
Sindbis virus was produced from electroporated BHK cells grown
in MEM/5% FBS according to published procedures (32). All cells
were grown at 37°C in 5% CO2 atmosphere.
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